Fierce Biotech July 11, 2024
The obesity game is only in its early innings, and the future market will be defined by who can ease administration of the medicines, according to a new report from Evaluate.
Market leaders Wegovy (Novo Nordisk) and Zepbound (Eli Lilly) are only capturing a fraction of the estimated $130 billion market that’s available, with less than $5 billion in sales clocked for the two drugs in 2023, Evaluate said in the World Preview 2024: Pharma’s Growth boost report issued Wednesday.
“The battle for market share has barely begun, and, by the end of the decade, there will likely be more than two in the fight,” Evaluate wrote.
With that kind of cash on the line, three of the top 10...
Today's Sponsors
Today's Sponsor